Hesperetin-7-methyl etherCAS# N/A |
| Cas No. | N/A | SDF | File under preparation. |
| PubChem ID | 14157910 | Appearance | Powder |
| Formula | C17H16O6 | M.Wt | 316.3 |
| Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
| Synonyms | 7-METHOXYHESPERETIN | ||
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-methoxy-2,3-dihydrochromen-4-one | ||
| SMILES | COC1=C(C=C(C=C1)C2CC(=O)C3=C(C=C(C=C3O2)OC)O)O | ||
| Standard InChIKey | LWBHKKLWSUFUNZ-HNNXBMFYSA-N | ||
| Standard InChI | InChI=1S/C17H16O6/c1-21-10-6-12(19)17-13(20)8-15(23-16(17)7-10)9-3-4-14(22-2)11(18)5-9/h3-7,15,18-19H,8H2,1-2H3/t15-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Description | Hesperetin-7-methyl ether is a natural prooduct from Citrus maxima. |
| Targets | PDE |
| Structure Identification | J Pharm Sci. 2013 Jul;102(7):2120-7.Inhibitory effects of hesperetin derivatives on guinea pig phosphodiesterases and their ratios between high- and low-affinity rolipram binding.[Pubmed: 23666855]
The phosphodiesterase (PDE)4 molecule exists as two distinct conformers, PDE4H and PDE4L , which have high and low affinities, respectively, for the selective PDE4 inhibitor, rolipram.
The inhibition of PDE4H and PDE4L is associated with adverse responses, such as nausea, vomiting, and gastric hypersecretion, and with anti-inflammatory and bronchodilator effects, respectively.
|
Hesperetin-7-methyl ether Dilution Calculator
Hesperetin-7-methyl ether Molarity Calculator
-
PersicogeninCatalog No.: BCN7744CAS No.: 28590-40-1 -
7,3',4'-Tri-O-methyleriodictyolCatalog No.: BCN7766CAS No.: 70987-96-1 -
HesperetinCatalog No.: BCN5657CAS No.: 520-33-2 -
(Rac)-HesperetinCatalog No.: BCN0325CAS No.: 69097-99-0 -
Eriodictyol 7,3'-dimethyl etherCatalog No.: BCN8105CAS No.: 54352-60-2 -
7-O-MethyleriodictyolCatalog No.: BCN5648CAS No.: 51857-11-5 -
4',7-Di-O-methylnaringeninCatalog No.: BCN5197CAS No.: 29424-96-2 -
SakuranetinCatalog No.: BCN5199CAS No.: 2957-21-3 -
(RS)-SakuranetinCatalog No.: BCN0343CAS No.: 520-29-6 -
PinostrobinCatalog No.: BCN5555CAS No.: 480-37-5 -
BlumeatinCatalog No.: BCN6055CAS No.: 118024-26-3 -
3',5-Dihydroxy-4',6,7-trimethoxyflavanoneCatalog No.: BCN0183CAS No.: 90850-99-0 -
HomoeriodictyolCatalog No.: BCN6804CAS No.: 446-71-9 -
IsosakuranetinCatalog No.: BCN5559CAS No.: 480-43-3 -
Hesperetin 7-O-glucosideCatalog No.: BCN5237CAS No.: 31712-49-9 -
Naringenin trimethyl etherCatalog No.: BCN5437CAS No.: 38302-15-7 -
TsugafolinCatalog No.: BCN4026CAS No.: 66568-97-6 -
PersicosideCatalog No.: BCN4780CAS No.: 28978-03-2 -
Blumeatin BCatalog No.: BCN4335CAS No.: 79995-67-8 -
2,3-Dihydroamentoflavone 7,4'-dimethyl etherCatalog No.: BCN1320CAS No.: 873999-88-3 -
2,3-dihydrosciadopitysinCatalog No.: BCN4034CAS No.: 34421-19-7 -
5,7-Dihydroxy-3',4',5'-trimethoxyflavanoneCatalog No.: BCN0136CAS No.: 62252-10-2 -
EriodictyolCatalog No.: BCN1209CAS No.: 552-58-9 -
(+/-)-EriodictyolCatalog No.: BCN0319CAS No.: 4049-38-1 -
4'-O-MethyllicoflavanoneCatalog No.: BCN4827CAS No.: 1038753-13-7 -
5,7-DimethoxyflavanoneCatalog No.: BCN3569CAS No.: 1036-72-2 -
5-O-MethylnaringeninCatalog No.: BCN4144CAS No.: 61775-19-7 -
(2R)-5,7-DimethoxyflavanoneCatalog No.: BCN7806CAS No.: 1277188-85-8 -
Naringenin-4',7-diacetateCatalog No.: BCN1144CAS No.: 18196-13-9 -
HesperidinCatalog No.: BCN5654CAS No.: 520-26-3
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.1616 mL | 15.8078 mL | 31.6156 mL | 63.2311 mL | 79.0389 mL |
| 5 mM | 0.6323 mL | 3.1616 mL | 6.3231 mL | 12.6462 mL | 15.8078 mL |
| 10 mM | 0.3162 mL | 1.5808 mL | 3.1616 mL | 6.3231 mL | 7.9039 mL |
| 50 mM | 0.0632 mL | 0.3162 mL | 0.6323 mL | 1.2646 mL | 1.5808 mL |
| 100 mM | 0.0316 mL | 0.1581 mL | 0.3162 mL | 0.6323 mL | 0.7904 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
- Junicedric acid
Catalog No.:BCN7660
CAS No.:41787-69-3
- Hypecorinine
Catalog No.:BCN3298
CAS No.:41787-57-9
- H-Leu-pNA.HCl
Catalog No.:BCC2972
CAS No.:4178-93-2
- Lenvatinib (E7080)
Catalog No.:BCC1172
CAS No.:417716-92-8
- 14-Deoxyandrographolide
Catalog No.:BCN3706
CAS No.:4176-97-0
- ar-Curcumene
Catalog No.:BCN7534
CAS No.:4176-06-1
- Evonimine
Catalog No.:BCN3082
CAS No.:41758-69-4
- Dihydrophaseic acid
Catalog No.:BCN5478
CAS No.:41756-77-8
- Ophiopogonin D
Catalog No.:BCN5004
CAS No.:41753-55-3
- Ginsenoside Rb1
Catalog No.:BCN1063
CAS No.:41753-43-9
- Acuminatin
Catalog No.:BCN5477
CAS No.:41744-39-2
- (-)-Sativan
Catalog No.:BCN7752
CAS No.:41743-86-6
- Mangiferolic acid
Catalog No.:BCN4636
CAS No.:4184-34-3
- Alatamine
Catalog No.:BCN3100
CAS No.:41855-33-8
- Bezafibrate
Catalog No.:BCC4639
CAS No.:41859-67-0
- 2,3-DCPE hydrochloride
Catalog No.:BCC2384
CAS No.:418788-90-6
- PYR-41
Catalog No.:BCC4470
CAS No.:418805-02-4
- Nitrocefin
Catalog No.:BCC6544
CAS No.:41906-86-9
- Isopropyl 4-Hydroxybenzoate
Catalog No.:BCN8409
CAS No.:4191-73-5
- Trilobatin
Catalog No.:BCN5479
CAS No.:4192-90-9
- N1-Methyl-4-nitrobenzene-1,2-diamine
Catalog No.:BCC9070
CAS No.:41939-61-1
- MLR 1023
Catalog No.:BCC6232
CAS No.:41964-07-2
- Pinocembrin chalcone
Catalog No.:BCN7223
CAS No.:4197-97-1
- Glabranin
Catalog No.:BCN5480
CAS No.:41983-91-9
Inhibitory effects of hesperetin derivatives on guinea pig phosphodiesterases and their ratios between high- and low-affinity rolipram binding.[Pubmed:23666855]
J Pharm Sci. 2013 Jul;102(7):2120-7.
The phosphodiesterase (PDE)4 molecule exists as two distinct conformers, PDE4H and PDE4L , which have high and low affinities, respectively, for the selective PDE4 inhibitor, rolipram. The inhibition of PDE4H and PDE4L is associated with adverse responses, such as nausea, vomiting, and gastric hypersecretion, and with anti-inflammatory and bronchodilator effects, respectively. We determined the therapeutic (PDE4H/PDE4L) ratios of hesperetin-7-O-methylether, hesperetin-5,7,3'-O-trimethylether (HTME), hesperetin-7-O-acetate, hesperetin-7,3'-O-diacetate, hesperetin-5,7,3'-O-triacetate (HTA), hesperetin-5,7,3'-O-tripropionate, hesperetin-5,7,3'-O-tributyrate, hesperetin-5,7,3'-O-triisobutyrate, and hesperetin-5,7,3'-O-tripivatate, and compared these ratios to those of hesperetin, hesperetin-7,3'-O-dimethylether, hesperidin, and hesperidin-3'-O-methylether to identify derivatives with therapeutic ratios and to characterize the structure-activity relationships among these compounds. The activities of PDE isozymes 1 through 5 were measured using a two-step procedure using [(3)H]adenosine 3',5'-cyclic monophosphate or [(3)H]guanosine 3',5'-cyclic monophosphate as substrates. The inhibitory concentration (IC50) for 50% of PDE4 inhibition and effective concentration (EC50) for replacing 50% of [(3)H]rolipram binding on high-affinity rolipram-binding sites was taken as the PDE4L and PDE4H value, respectively. The HTME and the HTA dually inhibited PDE3 and PDE4, and displayed PDE4H/PDE4L ratios of 18.3 and 20.8, respectively, suggesting that they may be candidate drugs for treating asthma and chronic obstructive pulmonary disease (COPD) because the combined inhibition of PDE3 and PDE4 has synergistically anti-inflammatory and bronchodilator effects in COPD patients.
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
